Neovascular Age-Related Macular Degeneration (nAMD)Phase 3NCT07317934
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
A Phase 3 study testing LX102 and Aflibercept in people with Neovascular Age-Related Macular Degeneration (nAMD) and Wet AMD, run by Innostellar Biotherapeutics Co.,Ltd at 36 sites in China.
Trial summary
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. Read more about this study
- Who is it for?
- Ages 50 to 80 years
- Conditions the study is for
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- What is being tested?
- LX102 and Aflibercept
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 388 participants
- Where
- 36 sitesChina
- Study dates
- 14 Jan 2026to 4 Jun 2032
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Willing and able to provide written, signed informed consent for this study;
- Age ≥50 and ≤80 years old;
- Active CNV secondary to nAMD in the study eye confirmed by FFA or OCT;
- The BCVA between 24 and 78 letters (inclusive) in the study eye at Screening;
- Demonstrated clinical response to aflibercept treatments in the study eye confirmed by the Reading Center;
- No anti-VEGF therapy in study eye within 28 days before screening;
- Must be pseudophakic in the study eye.
Who cannot join
- Any condition in the investigator's opinion that could limit VA improvement in the study eye.
- CNV or macular edema in the study eye secondary to any causes other than AMD
- Subfoveal atrophy in the study eye, as determined by CRC;
- History of retinal detachment in the study eye at any time;
- History of idiopathic or autoimmune uveitis in either eye;
- Advanced glaucoma in the study eye;
Show all 10Show fewer
- History of vitrectomy surgery in the study eye;
- History of intraocular surgery within 1 month before screening in the study eye;
- History of ocular or systemic gene therapy;
- Recent myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months.
Trial locations and contacts
36 sites in 1 country. Contact the study team or a site near you to ask about taking part.
36 sites in 1 country
China36 sites, 36 recruiting
- Recruiting
Beijing Aier-Intech Eye Hospital
Beijing, Beijing Municipality, 100000
Principal Investigator, +86 010-67715558-432, med@innostellarbio.com
- Recruiting
Beijing Hospital
Beijing, Beijing Municipality, 100730
Principal Investigator, +86 010-85136109, med@innostellarbio.com
- Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730
Principal Investigator, +86 010-69155180, med@innostellarbio.com
- Recruiting
The Second Hospital of Jilin University
Changchun, Jilin, 130022
Principal Investigator, +86 0431-88796522, med@innostellarbio.com
- Recruiting
The Second Xiangya Hospital, Central South University
Changsha, Hunan, 410011
Principal Investigator, +86 0731-85292097, med@innostellarbio.com
- Recruiting
Aier Eye Hospital Group Co., LTD. Changsha Aier Eye Hospital
Changsha, Hunan, 410015
Principal Investigator, +86 0731-85223462, med@innostellarbio.com
- Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041
Principal Investigator, +86 028-85422654, med@innostellarbio.com
- Recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 646100
Principal Investigator, +86 028-87393401, med@innostellarbio.com
- Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400010
Principal Investigator, +86 023-62888436, med@innostellarbio.com
- Recruiting
Southwest Hospital
Chongqing, Chongqing Municipality, 400038
Principal Investigator, +86 023-68754035, med@innostellarbio.com
- Recruiting
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, 510632
Principal Investigator, +86 020-38688366, med@innostellarbio.com
- Recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 310014
Principal Investigator, +86 0571-85893643, med@innostellarbio.com
- Recruiting
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150001
Principal Investigator, +86 0451-86664367, med@innostellarbio.com
- Recruiting
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230601
Principal Investigator, +86 0551-62282931, med@innostellarbio.com
- Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, 250012
Principal Investigator, +86 0531-82169347, med@innostellarbio.com
- Recruiting
Shandong Eye Hospital
Jinan, Shandong, 250021
Principal Investigator, +86 0531-81276007, med@innostellarbio.com
- Recruiting
The Affiliated Eye Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029
Principal Investigator, +86 025-86677709, med@innostellarbio.com
- Recruiting
Qingdao Eye Hospital Affiliated to Shandong First Medical University
Qingdao, Shandong, 266071
Principal Investigator, +86 0532-85899231, med@innostellarbio.com
- Recruiting
Eye & ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, 200031
Principal Investigator, +86 021-34232762, med@innostellarbio.com
- Recruiting
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080
associate professor, 021-36126255, shiyigcp@126.com
- Recruiting
Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200092
Principal Investigator, +86 021-25078693, med@innostellarbio.com
- Recruiting
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 201801
Principal Investigator, +86 021-64370045, med@innostellarbio.com
- Recruiting
Joint Shantou International Eye Center, Shantou University and the Chinese University of Hong Kong
Shantou, Guangdong, 515041
Principal Investigator, +86 0754-88393516, med@innostellarbio.com
- Recruiting
Shenyang Fourth People's Hospital
Shenyang, Liaoning, 110000
Principal Investigator, +86 024-8620-3666, med@innostellarbio.com
- Recruiting
Shanxi Eye Hospital
Taiyuan, Shanxi, 030002
Principal Investigator, +86 0351-8286926, med@innostellarbio.com
- Recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, 030032
Principal Investigator, +86 0351-8379146, med@innostellarbio.com
- Recruiting
Tianjin Eye Hospital
Tianjin, Tianjin Municipality, 300020
Principal Investigator, +86 022-27313336-80162, med@innostellarbio.com
- Recruiting
Tianjin Medical University Eye Hospital
Tianjin, Tianjin Municipality, 300384
professor, 022-86428810, ec_tmueh@126.com
- Recruiting
The Eye Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325027
Principal Investigator, +86 0577-88075582, med@innostellarbio.com
- Recruiting
Tongji Hospital Tongji Medical College of HUST
Wuhan, Hubei, 430030
Principal Investigator, +86 027-83691785, med@innostellarbio.com
- Recruiting
Central Theater Command General Hospital of PLA
Wuhan, Hubei, 430060
Principal Investigator, +86 027-50772994, med@innostellarbio.com
- Recruiting
Xi 'an People's Hospital (Xi 'an No.4 Hospital)
Xi’an, Shanxi, 710004
Principal Investigator, +86 029-89623908, med@innostellarbio.com
- Recruiting
The First Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, 710032
Principal Investigator, +86 029-84771794, med@innostellarbio.com
- Recruiting
Hebei Eye Hospital
Xingtai, Hebei, 054000
Principal Investigator, +86 0319-3237661, med@innostellarbio.com
- Recruiting
Xuzhou First People's Hospital
Xuzhou, Jiangsu, 221002
Principal Investigator, +86 0516-68380774, med@innostellarbio.com
- Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Zhongshan, Guangdong, 510623
professor, 020-66610720, zoccrc@mail.sysu.edu.cn
About this study
Official title: A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 48 and 56.
- Being tested
- LX102, Aflibercept
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LX102Genetic
Study eyes will receive a single subretinal injection of LX102.
AfliberceptBiological
Study eyes will receive 3 monthly loading doses of aflibercetp 2mg IVT and aflibercept 2mg IVT every 8 weeks.
| Study group | Role | What they receive |
|---|---|---|
| LX102 | Experimental | Not described Receives: Genetic: LX102 |
| Aflibercept | Active comparator | Not described Receives: Biological: Aflibercept |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean change from D0 in BCVA based on an average at weeks 48 and 56.
Mean change from D0 in BCVA as measured by the early treatment diabetic retinopathy study (ETDRS) visual acuity chart based on an average at weeks 48 and 56.
Measured: Week 56
Secondary outcomes (9)
Proportion of participants with improved BCVA
Proportion of participants with improved BCVA at week 56 and week 104
Measured: Week 56 and week 104
Proportion of participants with worsened BCVA
Proportion of participants with worsened BCVA at week 56 and week 104
Measured: Week 56 and week 104
Mean change from D0 in CST based on an average at weeks 48 and 56
Mean change from D0 in central subfield thickness (CST) based on an average at weeks 48 and 56
Measured: Week 56
Proportion of participants without SRF/IRF on OCT at week 56
Proportion of participants without SRF/IRF on OCT at week 56
Measured: Week 56
Proportion of participants who were supplemental anti-VEGF injection-free
Proportion of participants with no supplemental anti-VEGF injection through 56 weeks
Measured: Through 56 weeks
Proportion of participants who received 1 or 2 aflibercept injections
Proportion of participants received ≤2 supplemental anti-VEGF injections through 56 weeks
Measured: Through 56 weeks
Supplemental anti-VEGF injection annualized rate after LX102 administration through Week 56
Mean annualized number of anti-VEGF injections after LX102 administration through 56 weeks.
Measured: Through 56 weeks
Incidence of ocular and nonocular AEs and SAEs
Incidence of Adverse events (AE) and Serious adverse events (SAE) over 56 weeks
Measured: 56 weeks
Immunogenicity characteristics of LX102
Immunogenicity measurements (LX102 randomized participants) ; measure description: Immunogenicity measurements (vector shedding, serum antibodies to AAV2 and serum antibodies to LX102 TP)
Measured: 56 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2026
- Study start14 Jan 2026
- Primary completionMar 2028 (estimated)
- Study completion4 Jun 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neovascular Age-Related Macular Degeneration (nAMD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 388 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Innostellar Biotherapeutics Co.,Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07317934
- Sponsor's protocol ID
- INNOSTELLAR-LX102A03
- Status last verified
- Aug 2026
- First submitted
- 19 Dec 2025
- Last updated
- 6 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial
- ClinicalTrials.gov ID
- NCT07317934
- Acronym / sponsor ID
- INNOSTELLAR-LX102A03
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 388 participants (estimated)
- Lead sponsor
- Innostellar Biotherapeutics Co.,LtdIndustry (pharma, biotech, devices)
- Study start
- 14 Jan 2026 (actual)
- Primary completion
- Mar 2028 (estimated)
- Study completion
- 4 Jun 2032 (estimated)
- First posted
- 5 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 48 and 56.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LX102 | Experimental | Genetic: LX102 |
| Aflibercept | Active comparator | Biological: Aflibercept |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Willing and able to provide written, signed informed consent for this study;
- Age ≥50 and ≤80 years old;
- Active CNV secondary to nAMD in the study eye confirmed by FFA or OCT;
- The BCVA between 24 and 78 letters (inclusive) in the study eye at Screening;
- Demonstrated clinical response to aflibercept treatments in the study eye confirmed by the Reading Center;
Key exclusion criteria (10 listed)
- Any condition in the investigator's opinion that could limit VA improvement in the study eye.
- CNV or macular edema in the study eye secondary to any causes other than AMD
- Subfoveal atrophy in the study eye, as determined by CRC;
- History of retinal detachment in the study eye at any time;
- History of idiopathic or autoimmune uveitis in either eye;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LX102Study eyes will receive a single subretinal injection of LX102. | Genetic | LX102 |
| AfliberceptStudy eyes will receive 3 monthly loading doses of aflibercetp 2mg IVT and aflibercept 2mg IVT every 8 weeks. | Biological | Aflibercept |
Primary outcome
Mean change from D0 in BCVA based on an average at weeks 48 and 56.
Time frame: Week 56
Mean change from D0 in BCVA as measured by the early treatment diabetic retinopathy study (ETDRS) visual acuity chart based on an average at weeks 48 and 56.
9 secondary outcomes
Proportion of participants with improved BCVA
Time frame: Week 56 and week 104
Proportion of participants with worsened BCVA
Time frame: Week 56 and week 104
Mean change from D0 in CST based on an average at weeks 48 and 56
Time frame: Week 56
Proportion of participants without SRF/IRF on OCT at week 56
Time frame: Week 56
Proportion of participants who were supplemental anti-VEGF injection-free
Time frame: Through 56 weeks
Proportion of participants who received 1 or 2 aflibercept injections
Time frame: Through 56 weeks
Supplemental anti-VEGF injection annualized rate after LX102 administration through Week 56
Time frame: Through 56 weeks
Incidence of ocular and nonocular AEs and SAEs
Time frame: 56 weeks
Immunogenicity characteristics of LX102
Time frame: 56 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2026.
Related trials for Neovascular Age-Related Macular Degeneration (nAMD)
RecruitingPhase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
Not yet recruitingPhase 2
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
Neovascular Age Related Macular Degeneration(nAMD)
RecruitingPhase 1
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
nAMD
Active, not recruitingPhase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
RecruitingPhase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The First Affiliated Hospital of University of Science and Technology of China
Hefei, China
36 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing LX102 and Aflibercept in people with Neovascular Age-Related Macular Degeneration (nAMD) and Wet AMD, run by Innostellar Biotherapeutics Co.,Ltd at 36 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 36 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean change from D0 in BCVA based on an average at weeks 48 and 56. (time frame: Week 56). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.